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TO THE EDITOR
T lymphocytes express a variety of
voltage-gated potassium channels (Kv)
that greatly affect T-cell function (Szabo`
et al., 2010; Feske et al., 2012). Namely,
Kv1.3 channels regulate autoreactive
effector memory T cells, which are
implicated in the pathogenesis of
several autoimmune diseases (Beeton
et al., 2001, 2006, 2008; s4). Kv1.3
channel blockers may therefore offer
a therapeutic option in several auto-
immune disorders (Wulff et al., 2003a).
This may include alopecia areata (AA), a
T-cell–dependent autoimmune disease,
in which hair follicles (HFs) are attacked
by a dense lymphocytic infiltrate of
activated CD4þ and CD8þ T cells
(s9, s17, s15, Gilhar et al., 2012).
After grafting to SCID mice, lesional
(alopecic) scalp skin from AA patients
regrows hair when the infiltrating scalp
lymphocytes are lost (s14, s15, Gilhar
et al., 2012), whereas AA-like hair loss
can be induced in this humanized
mouse model of AA by injecting
lesional T cells (s13, s15). Previous
work by us and others had suggested
that NK cells and NKG2D ligands have a
major role in AA (Ito et al., 2008;
Petukhova et al., 2010). Moreover,
recently we demonstrated that it is
possible to induce AA lesions in healthy
human scalp transplants on SCID mice
only by injection of peripheral blood
mononuclear cells (PBMCs) greatly
enriched for NKG2Dþ and CD56þ
cells, which includes NK, NKT, and
some CD8þ T cells (Gilhar et al., 2013).
Therefore, we hypothesized that inhi-
biting T-cell function in AA by well-
tolerated Kv1.3 blockers may constitute
a therapeutic approach to AA manage-
ment, and asked the following ques-
tions: (1) Are Kv1.3þ T cells increased
in lesional AA skin? (2) Does Kv1.3-
selective potassium channel blockade
alter the development of AA lesions
in a humanized mouse model of AA
(Gilhar et al., 2013)?
First, we obtained biopsies from
lesional skin of 10 patients with AA
after informed consent and institutional
review board approval. Second, normal
scalp skin from healthy volunteers was
grafted onto beige SCID mice. ThreeAccepted article preview online 20 March 2013; published online 2 May 2013
Abbreviations: AA, alopecia areata; HFs, hair follicles; PBS, phosphate-buffered saline; PBMCs, peripheral
blood mononuclear cells
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months after skin engraftment and hair
regrowth, autologous PBMCs (from the
same healthy volunteers) that had been
enriched for NKG2Dþ /CD56þ cells,
which were stimulated in vitro with
IL-2, were injected intradermally into
the grafts. Within 4–6 weeks, this
induced a hair loss phenotype in the
human skin grafts that showed the
characteristic clinical and histological
features of human AA (Gilhar et al.,
2013).
Double-immunofluorescence con-
focal microscopy demonstrated the pre-
sence of multiple Kv1.3þ cells around
and within lesional HFs, both in the skin
of AA patients (Figure 1a) and in lesional
human skin in the humanized AA
mouse model (Figure 1b). The fact that
the perifollicular Kv1.3þ cells were
also CD3þ (Figures 1a, b) confirmed
that the Kv1.3þ cells are T lymphocytes.
In both lesional skin of AA patients and
in human skin transplanted onto SCID
mice with experimentally induced AA,
the number of Kv1.3þ T cells was
greatly increased compared with normal
skin of healthy volunteers and normal
hair graft (Po0.001) (Figure 1c).
Previous studies have demonstrated
that disease-associated autoreactive
T cells in type 1 diabetes mellitus, mul-
tiple sclerosis, and rheumatoid arthritis
are mainly negative for the chemokine
receptor, CCR7, but express Kv1.3
(Wulff et al., 2003b; Beeton et al.,
2006; s21). This phenotype may allow
one to distinguish autoreactive effector
memory T cells in patients with auto-
immune disease (s14). It is therefore
important to note that many of these
Kv1.3þ cells were CCR7 , both in AA
patients (47±2% of the total number
of Kv1.3þ cells) and in the humanized
AA mouse model (69±15%).
This suggests that most Kv1.3þ cells in
the inflammatory infiltrate in human AA
lesions represent autoreactive effector
memory T cells, which may have under-
gone repeated antigen stimulation in vivo
(s14). As Kv1.3 blockers preferentially
suppress autoreactive CCR7 effector
memory T cells that arise as a conse-
quence of repeated autoantigen stimula-
tion (Beeton et al., 2006), blocking the
Kv1.3 channel therefore promises greater
specificity for suppressing autoreactive
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Figure 1. Kv1.3/ CD3þ T cells in alopecia areata (AA) and human skin grafts transplanted onto SCID mice. (a) Double immunofluorescence demonstrates
the presence of Kv1.3þ /CD3þ cells around hair lesional hair follicles of AA patients and (b) in 11/15 human skin grafts injected with peripheral blood
mononuclear cells (PBMCs) greatly enriched for NKG2Dþ and CD56þ cells. Yet this was not seen in either normal skin of healthy volunteers (c) or in
(d) 10/13 grafts injected with the same PBMC preparation but also injected with PAP-1 instead of vehicle alone. Counterstain was performed with ToPro3
(blue nuclei), Kv1.3 (green), and CD3 (red). (e) A significant increase in the number of Kv1.3/CD3 double-positive cells was found in lesional skin of AA
patients compared with healthy scalp skin controls (3.8±1.2 vs. 0.1± 0.4, Po0.001). Similarly, a significantly increased number of Kv1.3/CD3 double-positive
cells was found in the humanized AA mouse model, as compared with lesional human AA scalp skin (P¼ 0.05) and with the PAP-1-treated responders
(Po0.05). Kv1.3þ /CD3þ cells were also largely absent in 7/8 human skin grafts injected with PHA-stimulated control PBMCs that had not developed AA lesions,
as expected (Gilhar et al., 2013).
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T cells than targeting other molecules
expressed on all T lymphocytes.
Encouraged by these findings, we
then probed in the humanized AA
mouse model (Gilhar et al., 2013)
whether the Kv1.3-selective potassium
channel blocker, 5-(4-phenoxybutoxy)
psoralen (PAP-1), has an impact on the
development of AA lesions in vivo. PAP-1
is a selective small-molecule blocker of
Kv1.3, which blocks Kv1.3 ( EC50:2nM)
and potently inhibits the proliferation of
human CCR7 T cells while sparing
naı¨ve and central memory T cells
(Schmitz et al., 2005, s18).
In line with our previously reported
results (Gilhar et al., 2013), after intrader-
mal injection of NKG2D/CD56-enriched,
IL-2-activated PBMCs, 11 out of 15 con-
trol grafts showed the expected, charac-
teristic focal alopecia (Figure 2a, b),
along with the histological (Figure 2c)
and immunohistochemical (Figure 2d)
features of AA. Double-immunofluore-
sence microscopy revealed that most
Kv1.3þ cells were CCR7 (Supple-
mentary Figure S1A–E online). PAP-1
or control vehicle injections were given
daily for 31 days, intradermally into
each graft, following injection of the
NKG2D/CD56-enriched cells.
In striking contrast to control mice, 10
out of 13 grafts in the five mice that had
9
P <0.005
Infiltrate
DP DP
HS
H
B
H
B
3.9
1.3
5.8
6.5
7.6
3.6
Vehicle-treated mice
PAP-1-treated mice
8
7
6
5
4
3
2M
ea
n 
ha
ir 
nu
m
be
r (
pe
r g
ra
ft)
1
0
Before
injection
Vehicle
PAP-1
Responders
(10/13 grafts)
Nonresponders
(3/13 grafts)
After
injection
Before
injection
After
injection
Before
injection
After
injection
Figure 2. The Kv1.3 blocker PAP-1 suppresses AA development in human skin grafts. Administration of Kv1.3 blocker inhibited the activity of
NKG2Dþ /CD56þ -enriched cells and thereby suppressed the development of AA. A stable number of hairs in the responder grafts (treated with both
NKG2Dþ /CD56þ cells and thereafter with PAP-1) clearly indicates a therapeutic benefit of PAP-1 injection in the humanized mouse of AA. Ten SCID mice,
grafted with normal human skin and injected with autologous NKG2Dþ /CD56þ -enriched cells, were used in this pilot study. Each mouse was grafted with three
scalp skin transplants obtained from the same donor (n¼30 grafts in total). Five mice were treated with the Kv1.3 blocker, PAP-1; the remaining five mice served
as a control group and were injected with vehicle only (Cremophor EL/PBS). (a) The mean hair number is increased after Kv1.3 blockade. A significantly increased
mean number of hairs was observed in PAP-1-treated responder grafts as compared with vehicle controls and with nonresponders (mean number of 5.8±2.1 vs.
3.9±1.5, P¼ 0.05, respectively). A similar mean number of hairs was observed in the responder grafts (11/15) before and after treatment with PAP-1.
However, significant hair loss was noted in grafts injected with NK-enriched cells and vehicle only (Po0.005), and in the nonresponder grafts from the
PAP-1-treated group (3/11, Po0.05). (b) As expected, complete AA-like hair loss was observed in human skin grafts injected with peripheral blood mononuclear
cells (PBMCs) greatly enriched for NKG2Dþ and CD56þ cells and treated only with vehicle (Gilhar et al., 2013). (c) Histological evaluation confirmed the
clinical observation of AA-like lesions by demonstrating the characteristic dense perifollicular lymphocytic infiltrates. (d) By performing immunohistochemistry,
ectopic HLA-DR expression within the hair follicle epithelium was demonstrated. (e) In sharp contrast to control mice only injected with NKG2Dþ /CD56þ cells
and vehicle, hair growth was observed in 3-mm grafts after treatment with PAP-1. This was accompanied by (f) histological and (g) immunohistochemical
normalization of the phenotype of PAP-1-treated grafts. DP, dermal papilla; HB, hair bulb; HS, hair shaft. Bar¼100mm.
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been treated with PAP-1 (6 mg kg1,
0.2 ml injection volume per graft)
showed complete hair regrowth
(Figure 2a, e) and complete histological
(Figure 2f) and immunohistological
normalization of the skin phenotype
(Figure 2g). In addition, quantitative
immunohistomorphometry revealed that
the number of Kv1.3þ /CD3þ cells
was significantly reduced in the respon-
der grafts (Figure 1d), compared with
either phosphate-buffered saline (PBS)-
treated control grafts or nonresponder
grafts (Figure 1e). Interestingly, Kv1.3
blockade by PAP-1 significantly reduced
the number of perifollicular and intra-
follicular Kv1.3þ cells even in the three
nonresponder grafts, as compared
with PBS-treated control AA lesions
(Figure 1e). As the cellular infiltrate in
spontaneously developed human AA
lesions and in the injected grafts that
developed AA lesions strongly expres-
sed Kv1.3, it is reasonable to assume
that the therapeutic effect of PAP-1
and its reduction of the number of
NKG2Dþ /CD56þ cells were owing
to its Kv1.3-blocking effects.
Taken together, these pilot data sug-
gest that Kv1.3þ /CCR7 TEM cells may
be both important elements in human
AA pathogenesis and promising targets
for more selective future immuno-
therapy of AA. Evidently, the robustness
of anti-AA effects of Kv1.3 blockers
needs to be confirmed in larger cohorts
of humanized AA mice (Gilhar et al.,
2013). However, the limited currently
available data are in line with promising
results obtained with Kv1.3 blockers
in other autoimmune disease (s10, s4;
Wulff et al., 2003b, 2009, Beeton
et al., 2006) and psoriasis models
(Gilhar et al., 2011). This encourages
one to systematically explore Kv1.3 block-
ade as a therapeutic strategy in human
AA (for additional background, methods,
discussion, and supplementary references,
see Supplementary Text online).
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Pharmacological Inhibition of Stearoyl CoA Desaturase in
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TO THE EDITOR
Acne is a multifactorial disease of
the pilosebaceous unit resulting from
increased sebum production, altered
keratinization, inflammation, and bac-
terial hypercolonization. With respect to
hyperseborrhea as one of the contribut-
ing factors, it is of interest to study
pathways that regulate sebaceous
gland differentiation. Interestingly,
mouse strains deficient in the enzyme
stearoyl-CoA desaturase 1 (SCD1) exhi-
bit severe hypoplasia of sebaceousAccepted article preview online 27 February 2013; published online 4 April 2013
Abbreviation: SCD, stearoyl-CoA desaturase
JG Meingassner et al.
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